Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2025
CompletedFirst Posted
Study publicly available on registry
November 3, 2025
CompletedNovember 3, 2025
September 1, 2025
September 18, 2025
October 31, 2025
Conditions
Keywords
Interventions
This study will utilize donor stool from an infant
Eligibility Criteria
You may qualify if:
- willingness of parent/guardian to sign ICF
- diagnosis of neuroblastoma
- dysbiosis of the gut microbiome
You may not qualify if:
- parent/guardian unwilling to sign ICF
- dysbiosis does not show a bifidobaceteria-bacteroides gap
- severely abnormal screening lab values
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ProgenaBiomelead
- Microbiome Research Foundationcollaborator
Study Sites (1)
ProgenaBiome
Ventura, California, 93003, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2025
First Posted
November 3, 2025
Last Updated
November 3, 2025
Record last verified: 2025-09